direct antithrombins

systematic review meta-analysis network meta-analysis

Select atrial fibrillationthrombosis prevention All type of patientorthopedic surgery       oral direct thrombin inhibitor dabigatranximelagatran vs anticoagulantvs Low molecular weight heparin      

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	Major bleeding (17)All cause death (10)Coronary event (7)total VTE and all-cause mortality (7)distal DVT (7)Venous thromboembolism (6)proximal DVT (6)major VTE (fatal and non fatal DVT,PE) (6)stroke (fatal and non fatal) (5)systemic thrombo-embolic complication (5)ischemic stroke (5)Haemmorhagic stroke (5)Fatal stroke (5)thrombo-embolic event (cerebral or systemic) (4)major or clinically relevant non-major bleeding (4)asymptomatic DVT (4)Symptomatic deep-vein thrombosis (4)non-fatal pulmonary embolism (4)Cardiovascular death (3)TE event or ischemic stroke or systemic embolism (3)Non fatal stroke (2)Lifethreatening major bleeding (2)Non-lifethreatening major bleeding (2)Gastrointestinal major bleeding (2)hypertransaminasemia (1)Fatal bleeding (1) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	Major bleeding	All cause death
atrial fibrillation
dabigatran
RE-LY (110mg), 2009      NCT	dabigatran 110mg	warfarin standard dose			Risk of bias	suggesting
PETRO (150mg), 2007	dabigatran 150mg	warfarin standard dose			Exploratory	-
RE-LY (150mg), 2009      NCT	dabigatran 150mg	warfarin standard dose			Risk of bias	suggesting
ximelagatran
SPORTIF II (ximelagatran vs warfarin standard dose), 2002	ximelagatran	warfarin standard dose			Risk of bias	-
SPORTIF III, 2003	ximelagatran	warfarin standard dose			Risk of bias	suggesting
SPORTIF V, 2005	ximelagatran	warfarin standard dose			Low risk of bias	suggesting
thrombosis prevention
dabigatran
RE-NOVATE (150mg), 2007      NCT	dabigatran 150mg	enoxaparin	hip surgery		Low risk of bias	negative
RE-NOVATE (220mg), 2007      NCT	dabigatran 220mg	enoxaparin	hip surgery		Low risk of bias	negative
RE-NOVATE 2    NCT	dabigatran 220mg	enoxaparin	hip surgery		Low risk of bias	negative
RE-MODEL (150mg), 2007	dabigatran 150mg	enoxaparin (europe regimen)	knee surgery		Low risk of bias	negative
RE-MODEL (220mg), 2007	dabigatran 220mg	enoxaparin (europe regimen)	knee surgery		Low risk of bias	negative
RE-MOBILIZE (150mg), 2008	dabigatran 150mg	enoxaparin (US regimen)	knee surgery		Low risk of bias	negative
RE-MOBILIZE (220mg), 2008	dabigatran 220mg	enoxaparin (US regimen)	knee surgery		Low risk of bias	negative
ximelagatran
METHRO I, 2002	ximelagatran	Dalteparin				negative
METHRO II, 2002	ximelagatran	Dalteparin			Low risk of bias	suggesting
Phase II (Heit), 2001	ximelagatran	Enoxaparin			Low risk of bias	negative
Platinum (Colwell), 2003	ximelagatran	Enoxaparin			Low risk of bias	negative
METHRO III, 2002	ximelagatran	Enoxaparin			Low risk of bias	negative
EXPRESS, 2003	ximelagatran	Enoxaparin			Low risk of bias	suggesting